AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15703143 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure tone audiometry (PTA)
Number of subjects: 2
Study 15703143 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoacoustic emission (OAE) testing
Number of subjects: 2
Study 15703143 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PTA and OAE)
Number of subjects: 2
Study 12135536 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall
Number of subjects: 0
Study 12135536 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 12135536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9516206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-sharing
Number of subjects: 35
Study 9516206 — intervention group
Group type: COMPARATOR
Intervention: Solitary sleeping
Number of subjects: 35
Study 7641173 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ml of ioversol 320 mg I/ml
Number of subjects: 100
Study 7641173 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 ml of ioversol 320 mg I/ml
Number of subjects: 100
Study 7641173 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of ioversol 320 mg I/ml
Number of subjects: 100
Study 7641173 — intervention group
Group type: COMPARATOR
Intervention: 120 ml of ioversol 320 mg I/ml
Number of subjects: 100
Study 29377181 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino Acid-based commercial ORT beverage
Number of subjects: 26
Study 29377181 — intervention group
Group type: COMPARATOR
Intervention: Sports drink (SP)
Number of subjects: 26
Study 27350420 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24031044 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure® (LS)
Number of subjects: 100
Study 24031044 — intervention group
Group type: COMPARATOR
Intervention: Stapler
Number of subjects: 100
Study 22728911 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder at 10-12 weeks post-treatment
Number of subjects: 62
Study 22728911 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder with incentive payment on clinic attendance
Number of subjects: 62
Study 22728911 — intervention group
Group type: COMPARATOR
Intervention: Standard advice from clinician (control group)
Number of subjects: 62
Study 20233429 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide
Number of subjects: 4
Study 20233429 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 4
Study 20233429 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 4
Study 20233429 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 4
Study 18755220 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir
Number of subjects: 0
Study 18755220 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of PEG-IFN alpha-2b and boceprevir
Number of subjects: 0
Study 17145598 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1g four times daily for 14 days
Number of subjects: 20
Study 17145598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15095779 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual FOB screening
Number of subjects: 2000
Study 15095779 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial FOB screening
Number of subjects: 2000
Study 10909264 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey-treated Pericarpium Citri Grandis decoction
Number of subjects: 6
Study 10909264 — intervention group
Group type: COMPARATOR
Intervention: Untreated Pericarpium Citri Grandis decoction
Number of subjects: 6
Study 8719187 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg bolus followed by 0.20 mg/kg‐1/min‐1 infusion)
Number of subjects: 16
Study 8719187 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (90 micrograms/kg 2 min before induction) followed by half-strength propofol (1 mg/kg bolus with 0.10 mg/kg‐1/min‐1 infusion)
Number of subjects: 16
Study 1574844 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaussian‐truncated sinewave gratings with varying stimulus contrast and bandwidth
Number of subjects: 2
Study 1574844 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaussian‐truncated sinewave gratings with constant spatial frequency bandwidth (0.5 octave) and suprathreshold contrast value (5 x detection threshold)
Number of subjects: 2
Study 1574844 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference spatial frequency gratings varying from 1 to 8 c/deg
Number of subjects: 2
Study 4065186 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 8
Study 4065186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4065186 — intervention group
Group type: COMPARATOR
Intervention: Carbachol
Number of subjects: 8
Study 30498037 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 70
Study 30498037 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 70
Study 27797931 — intervention group
Group type: EXPERIMENTAL
Intervention: HypoAware intervention
Number of subjects: 137
Study 27797931 — intervention group
Group type: COMPARATOR
Intervention: Control (care as usual)
Number of subjects: 137
Study 25740578 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 60
Study 25740578 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 60
Study 22728633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius (4x10^9 colony forming units/g daily for 12 weeks)
Number of subjects: 199
Study 22728633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 12 weeks)
Number of subjects: 199
Study 19951274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (up to 9 mg/day)
Number of subjects: 50
Study 19951274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19036143 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy with Paclitaxel (50 mg/m2) and Carboplatin (AUC = 2) followed by surgery
Number of subjects: 350
Study 19036143 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 350
Study 16174497 — intervention group
Group type: EXPERIMENTAL
Intervention: MTPJ arthrodesis
Number of subjects: 63
Study 16174497 — intervention group
Group type: COMPARATOR
Intervention: MTPJ arthroplasty
Number of subjects: 63
Study 12970783 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard induction chemotherapy regimen (TAD 2+7) with GM-CSF
Number of subjects: 93
Study 12970783 — intervention group
Group type: COMPARATOR
Intervention: Standard induction chemotherapy regimen (TAD 2+7) without GM-CSF
Number of subjects: 93
Study 11605609 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention program including motor, cognitive, speech development and social behavior.
Number of subjects: 156
Study 11605609 — intervention group
Group type: COMPARATOR
Intervention: Conventional care group (control).
Number of subjects: 156
Study 8681919 — intervention group
Group type: EXPERIMENTAL
Intervention: IMB model‐based intervention
Number of subjects: 0
Study 8681919 — intervention group
Group type: COMPARATOR
Intervention: No‐treatment control condition
Number of subjects: 0
Study 2052056 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4000 mg per day)
Number of subjects: 184
Study 2052056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (low dose, 1200 mg per day)
Number of subjects: 184
Study 2052056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (high dose, 2400 mg per day)
Number of subjects: 184
Study 6361788 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg
Number of subjects: 0
Study 6361788 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 400 mg
Number of subjects: 0
Study 6361788 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 0
Study 6361788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28556500 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha therapy in Group I (n = 15)
Number of subjects: 34
Study 28556500 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II, n = 19)
Number of subjects: 34
Study 28556500 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline evaluation for all patients
Number of subjects: 34
Study 28556500 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSG results for all patients
Number of subjects: 34
Study 28556500 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSQI and snoring score in Group I
Number of subjects: 34
Study 28556500 — intervention group
Group type: EXPERIMENTAL
Intervention: PSG parameters at third month of anti-TNF-alpha therapy in Group I
Number of subjects: 34
Study 27451927 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet-B
Number of subjects: 63
Study 27451927 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen plus ultraviolet-A
Number of subjects: 63
Study 27451927 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadband ultraviolet-A
Number of subjects: 63
Study 27451927 — intervention group
Group type: COMPARATOR
Intervention: Control group (sun-protected skin from 21 subjects with no dermatological disease)
Number of subjects: 63
Study 24757146 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NEXA)
Number of subjects: 100
Study 24757146 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps strengthening (QS)
Number of subjects: 100
Study 23571259 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with Ologen implant
Number of subjects: 33
Study 23571259 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with Mitomycin C (MMC)
Number of subjects: 33
Study 20100913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamapimod (300 mg once daily for 10 days)
Number of subjects: 22
Study 20100913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 22
Study 17445309 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day prophylactic antibiotic
Number of subjects: 53
Study 17445309 — intervention group
Group type: COMPARATOR
Intervention: Three-day prophylactic antibiotic
Number of subjects: 53
Study 16627043 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIDFORM 0-30 min before intercourse
Number of subjects: 20
Study 16627043 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIDFORM 8-10 h before intercourse
Number of subjects: 20
Study 16627043 — intervention group
Group type: COMPARATOR
Intervention: N-9 0-30 min after a control cycle
Number of subjects: 20
Study 16627043 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIDFORM (general use)
Number of subjects: 20
Study 15378774 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b 3 MU/TIW for 6 months in group Ia (N=15)
Number of subjects: 138
Study 15378774 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b 3 MU/TIW for 6 months in group Ib (N=17)
Number of subjects: 138
Study 15378774 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha 2b 3 MU/TIW for 6 months in group II (N=62)
Number of subjects: 138
Study 11048993 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab plus dual immunosuppressive therapy (cyclosporine modified [Neoral] and corticosteroids)
Number of subjects: 346
Study 11048993 — intervention group
Group type: COMPARATOR
Intervention: Placebo with dual immunosuppressive therapy (cyclosporine modified [Neoral] and corticosteroids)
Number of subjects: 346
Study 9066996 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cigarette consumption (20 or more cigarettes per day)
Number of subjects: 559
Study 9066996 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to neuroleptics
Number of subjects: 559
Study 9066996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyskinetic group (mean Abnormal Involuntary Movements Scale score)
Number of subjects: 559
Study 8389026 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 4 mg
Number of subjects: 51
Study 8389026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 3303885 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 10
Study 3303885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30354996 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TMAO levels (measured in μmol/L)
Number of subjects: 1244
Study 30354996 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TMAO levels (≥1.79 μmol/L)
Number of subjects: 1244
Study 30354996 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TMAO levels (≥3.19 μmol/L)
Number of subjects: 1244
Study 30354996 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between TMAO and folate levels (≥7.7 ng/mL versus <7.7 ng/mL)
Number of subjects: 1244
Study 27769274 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 20
Study 27769274 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 20
Study 25031198 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide + metformin
Number of subjects: 40
Study 25031198 — intervention group
Group type: COMPARATOR
Intervention: placebo + metformin
Number of subjects: 40
Study 22499010 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug conservation arm (440 subjects)
Number of subjects: 876
Study 22499010 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral suppression arm (436 subjects)
Number of subjects: 876
Study 20139214 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antibiotics
Number of subjects: 309
Study 20139214 — intervention group
Group type: EXPERIMENTAL
Intervention: Midstream urine
Number of subjects: 309
Study 20139214 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick
Number of subjects: 309
Study 20139214 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom score
Number of subjects: 309
Study 20139214 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotics
Number of subjects: 309
Study 18843900 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole 500 mg twice a day for seven days
Number of subjects: 84
Study 18843900 — intervention group
Group type: EXPERIMENTAL
Intervention: One vaginal tablet containing freeze-dried Lactobacillus rhamnosus once a week at bedtime for two months starting one week after the last antibiotic administration
Number of subjects: 84
Study 15838410 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated care suggestions for CHF
Number of subjects: 774
Study 12218528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (0.1 mg/kg) immediately after loss of consciousness (Group A)
Number of subjects: 30
Study 12218528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium after 15 min of anesthesia with propofol alone (Group B)
Number of subjects: 30
Study 12218528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium after 15 min of anesthesia with propofol and N O (Group C)
Number of subjects: 30
Study 12218528 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 30
Study 10487666 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment at 6 IU/m2 body surface-day
Number of subjects: 79
Study 10487666 — intervention group
Group type: COMPARATOR
Intervention: GH treatment at 3 IU/m2 body surface-day
Number of subjects: 79
Study 10487666 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (both doses)
Number of subjects: 79
Study 8598656 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential pneumatic compression devices during surgery and 2 days postoperatively (Group 1, n = 25)
Number of subjects: 108
Study 8598656 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (5000 U q 12 hr) starting 1 hr before surgery and for 7 days postop (Group 2, n = 38)
Number of subjects: 108
Study 8598656 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control Group 3, n = 45)
Number of subjects: 108
Study 2063698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine fading with enriched cohesion
Number of subjects: 353
Study 2063698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine fading with standard cohesion
Number of subjects: 353
Study 2063698 — intervention group
Group type: COMPARATOR
Intervention: Satiation technique
Number of subjects: 353
Study 6276949 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous nutrition (PIVN) with chemotherapy (adriamycin, vincristine, VP-16-213, and cyclophosphamide)
Number of subjects: 39
Study 6276949 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy control group
Number of subjects: 39
Study 6276949 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous nutrition (PIVN) with chemotherapy
Number of subjects: 39
Study 6276949 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PIVN and control)
Number of subjects: 39
Study 30232094 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) with a paper guideline to target glucose control (2.6-10 mmol/L)
Number of subjects: 20
Study 30232094 — intervention group
Group type: COMPARATOR
Intervention: Standard neonatal care (masked CGM)
Number of subjects: 20
Study 30232094 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 20
Study 27705875 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling-based learning control (SLC) approach with a gradient flow algorithm
Number of subjects: 0
Study 25664818 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion-controlled meals (PCMs) with fruits and vegetables and increased physical activity during weight loss (0-6 months)
Number of subjects: 197
Study 25664818 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion-controlled meals (PCMs) during weight maintenance (6-18 months)
Number of subjects: 197
Study 24336477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan SNAGs
Number of subjects: 86
Study 24336477 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland mobilizations
Number of subjects: 86
Study 24336477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 24336477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan SNAGs and Maitland mobilizations
Number of subjects: 86
Study 24336477 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Mulligan SNAGs, Maitland mobilizations, and placebo)
Number of subjects: 86
Study 22492681 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS (Physical Activity Leaders) intervention, n=50
Number of subjects: 100
Study 22492681 — intervention group
Group type: COMPARATOR
Intervention: Control group, n=50
Number of subjects: 100
Study 20123776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (in-hospital counseling session)
Number of subjects: 101
Study 20123776 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 101
Study 17636113 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (15 mg/kg 4 times a day)
Number of subjects: 77
Study 17636113 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (5 mg/kg 4 times a day)
Number of subjects: 77
Study 17636113 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 77
Study 17636113 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 77
Study 17636113 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen and Naproxen
Number of subjects: 77
Study 16082623 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-3 genotypes (5A5A, 5A6A, 6A6A)
Number of subjects: 455
Study 16082623 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-1 genotypes (4G4G, 4G5G, 5G5G)
Number of subjects: 455
Study 16082623 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-2, MMP-9, MMP-12 genotypes
Number of subjects: 455
Study 12237200 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid blockade (8 mg naloxone i.v.)
Number of subjects: 88
Study 12237200 — intervention group
Group type: COMPARATOR
Intervention: Placebo blockade (saline)
Number of subjects: 88
Study 10409478 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of sublingual 17beta-oestradiol (E(2))
Number of subjects: 30
Study 8536451 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexiGard IUD
Number of subjects: 4286
Study 8536451 — intervention group
Group type: COMPARATOR
Intervention: TCu 380A IUD
Number of subjects: 4286
Study 2209513 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 201
Study 2209513 — intervention group
Group type: COMPARATOR
Intervention: Whey-hydrolysate formula
Number of subjects: 201
Study 2209513 — intervention group
Group type: COMPARATOR
Intervention: Acidified formula
Number of subjects: 201
Study 2209513 — intervention group
Group type: COMPARATOR
Intervention: Whey-predominant formula
Number of subjects: 201
Study 2209513 — intervention group
Group type: COMPARATOR
Intervention: Casein-predominant formulae
Number of subjects: 201
Study 2209513 — intervention group
Group type: COMPARATOR
Intervention: Follow-up formulae
Number of subjects: 201
Study 2209513 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 201
Study 2209513 — intervention group
Group type: EXPERIMENTAL
Intervention: GOR
Number of subjects: 201
Study 6835896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meptazinol 100 mg
Number of subjects: 8
Study 6835896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31035395 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence score increase
Number of subjects: 1936
Study 31035395 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to the Mediterranean diet
Number of subjects: 1936
Study 31035395 — intervention group
Group type: COMPARATOR
Intervention: Obese participants
Number of subjects: 1936
Study 29980607 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 52
Study 29980607 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 52
Study 26218077 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine (5-AZA) at a dose of 75 mg/m2 s.c. administered on a schedule of 5 days on/weekend off/2 days on (5/2/2)
Number of subjects: 56